- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Mayzent
Synonyms :
siponimod
Class :
Neurologics, Sphingosine 1-Phosphate Receptor Modulators
Dosage Forms & Strengths
tablet
2mg
0.25mg
CYP2C9 genotypes Patients *1/*1, *1/*2, and *2/*2
Begin with a five-day titration
On day 6 Maintenance dose: 2 mg orally daily
Use a starter pack in patients titrated with a 2mg maintenance dose
Do not use the starting pack for patients titrated with a 1mg maintenance dose
Titration for the daily maintenance dosage of 2mg
Day 1: (1 x 0.25 mg) 0.25 mg orally
Day 2: (1 x 0.25 mg) 0.25 mg orally
Day 3: (2 x 0.25 mg) 0.50 mg orally
Day 4: (3 x 0.25 mg) 0.75 mg orally
Day 5: (5 x 0.25 mg) 1.25 mg orally
Day 6 and following days: (1 x 2 mg) 2 mg orally daily
CYP2C9 genotypes Patients *1/*3 and *2/*3
Begin with a four-day titration
On day 5 Maintenance dose: 1 mg orally daily
Do not use the starting pack for patients titrated with a 1mg maintenance dose
Titration for the daily maintenance dosage of 1mg
Day 1: (1 x 0.25 mg) 0.25 mg orally
Day 2: (1 x 0.25 mg) 0.25 mg orally
Day 3: (2 x 0.25 mg) 0.50 mg orally
Day 4: (3 x 0.25 mg) 0.75 mg orally
Day 5 and following days: (4 x 0.25 mg) 1 mg orally daily
Restarting therapy after an interruption
If maintenance therapy is discontinued for four or more consecutive daily doses following completing the initial titration, restart treatment on Day 1 of the titration regimen
Dose Adjustments
Dosage Modifications
Hepatic impairment
Dose adjustment is not required
Renal impairment
Dose adjustment is not required
ESRD or hemodialysis patients: Not studied
Safety and efficacy not established
Refer to the adult dosing regimen
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may reduce the therapeutic effect of vaccines
poliovirus vaccine, live, trivalent
may reduce the therapeutic effect of vaccines
poliovirus vaccine inactivated
may reduce the therapeutic effect of vaccines
measles, mumps, rubella, and varicella vaccine, live (Rx)
may reduce the therapeutic effect of vaccines
measles mumps and rubella vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
smallpox (vaccinia) vaccine, live
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may have an increased bradycardic effect when combined with siponimod
may decrease the therapeutic effect when combined with COVID-19 vaccine
immunosuppressants may diminish the therapeutic effect of vaccines
vaccinia immune globulin intravenous (Rx)
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
immunosuppressants may diminish the therapeutic effect of vaccines
may increase the bradycardia effect
may increase the bradycardic effect of bradycardiac agents
may increase the bradycardic effect of bradycardia causing agents
may enhance the serum concentrations of calcimimetic agents
may decrease the diagnostic effect when combined with coccidioides immitis skin test
may have an increased immunosuppressive effect when combined with denosumab
measles, mumps, rubella, and varicella vaccine, live (Rx)
may decrease the therapeutic effect of immunosuppressants
measles mumps and rubella vaccine, live
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
smallpox (vaccinia) vaccine, live
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect of immunosuppressants
may enhance the bradycardic effect of bradycardia causing agents
may increase the bradycardic effect of bradycardia causing agents
may have an increased immunosuppressive effect when combined with leflunomide
may decrease the therapeutic effect when combined with sipuleucel-t
may decrease the therapeutic effect when combined with covid-19 vaccine
may decrease the therapeutic effect when combined with influenza virus vaccines
influenza virus vaccine, h5n1, live
may decrease the therapeutic effect when combined with influenza virus vaccines
influenza virus vaccine (h5n1), adjuvanted
may decrease the therapeutic effect when combined with influenza virus vaccines
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both the drugs are combined, the risk or severity of adverse effects increases
when both drugs are combined, there may be an increased risk or severity of adverse effects
the effect of siponimod is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the effect of erdafitinib is increased by fluorouracil by the action on CYP2C9/10 hepatic enzyme metabolism
when both drugs are combined, there may be a decreased effect of siponimod by affecting hepatic or intestinal enzyme cyp3a4 metabolism
enzalutamide may reduce the therapeutic efficacy of siponimod
may increase the QTc interval when combined
may enhance the adverse/toxic effect
poliovirus vaccine, live, trivalent
may enhance the adverse/toxic effect
poliovirus vaccine inactivated
may enhance the adverse/toxic effect
may have an increasingly adverse effect when combined with talimogene laherparepvec
the immunosuppressive effect of immunosuppressants (cytotoxic chemotherapy) may be enhanced by abrocitinib
may have an increased immunosuppressive effect when combined with baricitinib
may have an increasingly adverse effect when combined with BCG products
respiratory syncytial virus vaccine, adjuvanted
may diminish the therapeutic effect of vaccines
respiratory syncytial virus (RSV) vaccine
may diminish the therapeutic effect of vaccines
Both siponimod and clofarabine enhance immunosuppressive effects
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
By immunosuppressive effects, the toxicity of the other drug increases and results in risk of infection.
when siponimod and melphalan combine the immunosuppressive effects of both the drugs are enhanced and lead to increased risk of infection
when both the drugs are combined, the immunosuppressive effects of both the drugs increases and lead to an increased risk of infection
additive immunosuppressive effects may raise the risk of severe infections
when both drugs are combined, there may be an increased immunosuppressive effect of both drugs and a risk of infection
increases immunosuppressive effects and increases the risk of serious infection
both the drugs increase the effect of immunosuppression risk of infection increases on administering both the drugs simultaneously
may increase excessive immunosuppressive effects
when used in combination, both the drugs increase immunosuppression/risk of infection
may increase excessive immunosuppressive effects
may increase excessive immunosuppressive effects
siponimod increases the effect of immunosuppression when used simultaneously with ixazomib
may increase the risk of excessive bone marrow suppression
when both drugs are combined, there may be an increased risk or severity of infection
when both drugs are combined, there may be an increased risk of infection
neratinib and siponimod, when used simultaneously, increase the effect of immunosuppression
increases immunosuppressive effects and increases the risk of serious infection
May enhances the effects of the other by pharmacodynamic synergism
may enhance the immunosuppressive effects of each other
may increase the risk or severity of hypertension when combined
may decrease the therapeutic effect when combined with pneumococcal vaccines
may decrease the therapeutic effect when combined with pidotimod
may decrease the therapeutic effect when combined with brincidofovir
may increase the immunosuppressive effect of immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
may have an increased immunosuppressive effect when combined with immunosuppressants
